Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA ...

Eli Lilly and Company enters the new trading week with significant momentum from a pivotal development in China. This comes ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

Ozempic (semaglutide) is a powerful and versatile drug, offering dual benefits: controlling blood sugar in type 2 diabetes, and facilitating weight loss as a secondary effect. While its primary ...

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.

Eli Lilly ( LLY) is cutting prices for starting doses of Zepbound single-dose vials on its LillyDirect direct-to-consumer platform.

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...